-
After developing Type 2 diabetes and having a heart attack in his 40s, Clearwater resident Fabricio Zambrano switched to a plant-based lifestyle.
-
In a leadership shakeup, the diet company says CEO Sima Sistani would leave her role effective immediately. Tara Comonte, a board member and former Shake Shack exec, was named interim chief.
-
Cheaper versions of Wegovy and Zepbound touted on social media could be fleeting. Copies are legal now because the brand-name drugs are in short supply. But the drugmakers are boosting production.
-
New research shows that the number of 12- to 25-year-olds who used the GLP-1 medications climbed from about 8,700 a month in 2020 to 60,000 a month in 2023.
-
The makers of Ozempic and Mounjaro charge charge around $1,000 a month for the drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
-
But some health experts worry about traditional diet companies and gyms getting in the medication business and believe the drugs will cater to society’s need for quick fixes.
-
It's our monthly medical roundtable, when we dive into the month's most significant health headlines.
-
Health officials say a preliminary review finds no connection between suicidal thoughts and a new class of diabetes and obesity drugs, but they cannot definitively rule out “a small risk may exist."
-
Many welcome what they say is greater control over what they eat. “I don’t care about the bread as much. I still eat what I enjoy,” says one Tampa area woman who lost more than 200 pounds taking Mounjaro.
-
New research finds that limiting eating from noon to 8 p.m. helped patients manage weight and blood sugar as much as calorie counting – and was easier to keep up.